Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Discussing new data available from ASCO 2023 on MDS with a focus on Bristol Myers' Reblozyl (luspatercept) COMMANDS trial and Geron's imetelstat IMerge Phase 2/3 study in patients with LR-MDS.

Ticker(s): BMY, GERN

Who's the expert?

Institution: Case Western Reserve University School of Medicine

Clinical Professor, Department of Medicine, School of Medicine and Member, Immune Oncology Program, Case Comprehensive Cancer Center
Research interests are focused on three major areas: 1) early phase cancer therapeutics, cellular and immunotherapies for blood cancers and other non-malignant disorders; 2) laboratory-based translational researches in normal and cancer stem cell signaling profiles and pre-clinical animal models for therapeutics.
treats over 50 patients a year with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
familiar with results from the final analysis of the phase 3 ALPINE trial

Interview Goal

This discussion will focus on MDS, specifically the new data available from ASCO 2023 from the Phase 3 COMMANDS trial comparing the efficacy and safety of Bristol Myers' luspatercept vs epoetin alfa in patients with transfusion dependent LR-MDS and from the Phase 2/3 IMerge trial evaluating Geron's imetelstat in patients with transfusion dependent LR-MDS.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.